Literature DB >> 32755196

Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.

Swayamjeet Satapathy1, Harmandeep Singh1, Rajender Kumar1, Bhagwant Rai Mittal1.   

Abstract

BACKGROUND. Early diagnosis is important in the overall management of prostate cancer (PCa). Gallium-68-labeled prostate-specific membrane antigen (PSMA) PET/CT has an established role in the detection of recurrent disease and staging of patients with intermediate- to high-risk PCa. However, only a small number of studies have evaluated its role in the initial diagnosis of PCa. OBJECTIVE. This systematic review was conducted to evaluate the diagnostic performance of 68Ga-PSMA PET/CT in the initial detection of PCa in patients with clinical or biochemical findings suspicious for PCa. EVIDENCE ACQUISITION. This systematic review followed PRISMA guidelines. Searches in PubMed, Scopus, and Embase were conducted using relevant keywords, and articles published through April 30, 2020, were included. Using histopathology results as the reference standard, the numbers of true- and false-positives and true- and false-negatives were extracted. Pooled estimates of diagnostic test accuracy-including sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and summary ROC (SROC) curve-were generated using bivariate random-effects meta-analysis. EVIDENCE SYNTHESIS. Seven studies comprising 389 patients were included in the systematic review and meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for the initial diagnosis of PCa using 68Ga-PSMA PET/CT were 0.97 (95% CI, 0.90-0.99), 0.66 (95% CI, 0.52-0.78), 2.86 (95% CI, 1.95-4.20), and 0.05 (95% CI, 0.01-0.15), respectively. The test had high accuracy; the area under the SROC curve was 0.91 (95% CI, 0.88-0.93). CONCLUSION. Gallium-68-labeled PSMA PET/CT had excellent sensitivity and negative likelihood ratio in the initial diagnosis of PCa in patients with clinical or biochemical findings suspicious for PCa. CLINICAL IMPACT. Gallium-68-labeled PSMA PET/CT had high diagnostic accuracy for the initial detection of PCa in patients with clinical or biochemical findings suspicious for PCa and has potential utility as a rule-out test for these patients.

Entities:  

Keywords:  68Ga-PSMA PET/CT; PSA; meta-analysis; prostate cancer; systematic review

Mesh:

Substances:

Year:  2021        PMID: 32755196     DOI: 10.2214/AJR.20.23912

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

Review 1.  Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CT vs PET-MRI.

Authors:  Feng-Yuan Liu; Ting-Wen Sheng; Jing-Ren Tseng; Kai-Jie Yu; Ke-Hong Tsui; Se-Tong Pang; Li-Jen Wang; Gigin Lin
Journal:  Br J Radiol       Date:  2021-12-21       Impact factor: 3.039

2.  68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer.

Authors:  Snir Dekalo; Jonathan Kuten; Jeffrey Campbell; Ishai Mintz; Yuval Bar-Yosef; Daniel Keizman; David Sarid; Einat Even-Sapir; Ofer Yossepowitch; Roy Mano
Journal:  Can Urol Assoc J       Date:  2022-07       Impact factor: 2.052

3.  Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer.

Authors:  Harmandeep Singh
Journal:  Indian J Nucl Med       Date:  2020-10-21

4.  SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer.

Authors:  Sheela Chinnappan; Piyush Chandra; John Santa Kumar; Ganesan Chandran; Satish Nath
Journal:  Indian J Nucl Med       Date:  2021-12-15

5.  Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging.

Authors:  Venkata Avinash Chikatamarla; Satomi Okano; Peter Jenvey; Alexander Ansaldo; Matthew J Roberts; Stuart C Ramsay; Paul A Thomas; David A Pattison
Journal:  EJNMMI Res       Date:  2021-12-20       Impact factor: 3.138

6.  Comparison of Multiparametric Magnetic Resonance Imaging and Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Detecting Carcinoma Prostate in Patients with Serum Prostate-Specific Antigen between 4 and 20 ng/ml.

Authors:  Brijesh Kumar Soni; Priyanka Verma; Amit Kumar Shah; Rajendra Singh; Sunita Sonawane; Ramesh V Asopa
Journal:  Indian J Nucl Med       Date:  2021-09-23

7.  Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study.

Authors:  Harsh Jain; Rajeev Sood; Mohammad Shazib Faridi; Hemant Goel; Umesh Sharma
Journal:  Cent European J Urol       Date:  2021-07-08

8.  Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis.

Authors:  Yi Zhao; Naomi Morka; Benjamin Scott S Simpson; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris
Journal:  BMJ Open       Date:  2021-12-10       Impact factor: 2.692

Review 9.  Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Sui Wai Ling; Anouk C de Jong; Ivo G Schoots; Kazem Nasserinejad; Martijn B Busstra; Astrid A M van der Veldt; Tessa Brabander
Journal:  Eur Urol Open Sci       Date:  2021-09-28

Review 10.  Molecular Mechanisms Related with Oligometastatic Prostate Cancer-Is It Just a Matter of Numbers?

Authors:  Cristian Surcel; Alexander Kretschmer; Cristian Mirvald; Ioanel Sinescu; Isabel Heidegger; Igor Tsaur
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.